Clinical Trials | June 15, 2024
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Subscribe To Our Newsletter & Stay Updated
